When was Alafair Biosciences founded?

Alafair Biosciences was founded in 2011 and raised its 1st funding round 1 year after it was founded.

Where is Alafair Biosciences located?

Alafair Biosciences is headquartered in Austin, United States.

Who is the current CEO of Alafair Biosciences?

Daniel Peterson of Alafair Biosciences.

How many employees does Alafair Biosciences have?

As of Sep 30, 2026, the latest employee count at Alafair Biosciences is 64.

Is Alafair Biosciences a funded company?

Alafair Biosciences is a funded company, having raised a total of $13.7M across 11 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 05, 2012.

When was the latest funding round of Alafair Biosciences?

Alafair Biosciences' latest funding was a $***** Series B round on Apr 18, 2019, with participation from 0 investor. Its primary sector is Wound Care. In United States, the Wound Care sector has seen $116M in funding in 2026 to date.

Where does Alafair Biosciences rank among its competitors?

Alafair Biosciences ranks 3rd amongst 159 active competitors, of which 18 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Nanordica Medical, which secured $1.85M in Jun, 2026.

Who are the top competitors of Alafair Biosciences?

Alafair Biosciences' top competitors include Imbed Biosciences, NuVision and Kane Biotech. Among them, Nanordica Medical secured the most recent funding round in June, 2026.

Alafair Biosciences - 2026 Company Profile, Team, Funding & Competitors

Company Details

Biomaterials and biomedical devices that enhance internal wound healing. It develops cross-linked polysaccharide hydrogel films to address the post-surgical complication of unwanted soft tissue attachments or tethering between opposing tissue surfaces.

Key Metrics

Founded Year

2011

Location

Austin, United States

Stage

Series B

Total Funding

$13.7M in 11 rounds

Latest Funding Round

Series B, Apr 18, 2019, $*****

Investors

ATP & 5 more

Ranked

3^rd among 159 active competitors

Employee Count

64 as on Sep 30, 2026

Similar Companies

Imbed Biosciences & 182 more

View Alafair Biosciences' full profile

Alafair Biosciences has raised a total funding of $13.7M over 11 rounds. Its first funding round was on Jan 05, 2012. Alafair Biosciences has 6 institutional investors.

Here is the list of recent funding rounds of Alafair Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 18, 2019	6297569	Series B	6169509	4537163	6931577	8098324
Oct 31, 2018	2552984	Series A	4595866	9269383	7160647	9208696
Jul 19, 2017	2943729	Conventional Debt	8200234	9923760	4528753	8768543

Access funding benchmarks and valuations. Sign up today!

View details of Alafair Biosciences's funding rounds and investors

Alafair Biosciences' employee count trend

Alafair Biosciences has 64 employees as of Sep 26. Here is Alafair Biosciences's employee count trend over the years:

Employee count trend for Alafair Biosciences

Uncover Alafair Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Alafair Biosciences include Imbed Biosciences, NuVision and Kane Biotech. Here is the list of Top 10 competitors of Alafair Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Imbed Biosciences 2010, Madison (United States), Series C	Provider of nanotech-based wound care products	$34.3M	Niterra, MassChallenge & 7 others	67/100
2nd	NuVision 2015, Nottingham (United Kingdom), Public	Developer of an ophthalmic therapies for ocular surface disease	$13.4M	Mercia, Nottingham Technology Ventures & 35 others	59/100
3rd	Alafair Biosciences 2011, Austin (United States), Series B	Biomaterials and biomedical devices that enhance internal wound healing	$13.7M	ATP, UT System & 4 others	58/100
4th	Kane Biotech 2001, Winnipeg (Canada), Public	Developer of therapeutic solutions to prevent and remove biofilms	-	Genesys Venture, National Research Council Canada ... & 2 others	55/100
5th	Cresilon 2010, New York City (United States), Series B	Developer of hemostatic products for wound care	$142M	Paulson Investment, Innovating Capital & 6 others	54/100
6th	Nanordica Medical 2019, Tallinn (Estonia), Seed	Provider of nanotech-based wound care products	$4.15M	Specialist, 2C Ventures & 9 others	50/100
7th	Lohmann & Rauscher 1998, Rengsdorf (Germany), Funding Raised	Dressing materials and medical devices	-	Austria Wirtschaftsservice, Gov.cz	50/100
8th	Symatese 2001, Chaponost (France), Funding Raised	Developer of hemostatic material and bone-subsitutes	-	Credit Mutuel Equity, Picardie Investissement	45/100
9th	Matricelf 2019, Tel Aviv (Israel), Funding Raised	Developer of spinal cord implants and regenerative medicine for treating spinal injury	-	MassChallenge	43/100
10th	Shanghai Haohai Biological Technology 2007, Jinzhong (China), Funding Raised	Manufacturer of absorbable biomedical materials.	-	DM Capital	43/100